Patents Assigned to AstraZeneca
  • Compounds 010
    Patent number: 7902181
    Abstract: The present invention provides compounds of formula (I) in which n, y, X1, X2, A, B, R1, R2, R3, R4 and R5 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: December 10, 2008
    Date of Patent: March 8, 2011
    Assignee: AstraZeneca AB
    Inventors: Mark Furber, Christopher Andrew Luckhurst, Hitesh Jayantilal Sanganee, Linda Anne Stein, Peter Alan Cage
  • Chemical compounds
    Patent number: 7902200
    Abstract: The invention relates to a novel group of compounds of Formula (I) or a salt thereof: wherein R1, A and HET-1 are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK) such as type 2 diabetes. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by GLK using said compounds and methods for preparing compounds of Formula (I).
    Type: Grant
    Filed: October 22, 2007
    Date of Patent: March 8, 2011
    Assignee: AstraZeneca AB
    Inventors: Leonie Campbell, Kurt Gordon Pike, Abid Suleman, Michael James Waring
  • Compounds
    Patent number: 7902189
    Abstract: There is provided a compound of formula I: or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.
    Type: Grant
    Filed: August 21, 2007
    Date of Patent: March 8, 2011
    Assignee: AstraZeneca AB
    Inventors: Heather Mary Ellen Duggan, Karine Malagu, Frederic Georges Marie Leroux, Niall Morrisson Barr Martin, Keith Allan Menear, Graeme Cameron Murray Smith
  • Diagnostic System and Method
    Publication number: 20110054931
    Abstract: A diagnostic system and method. In one embodiment, the invention is a diagnostic system comprising: a form comprising one or more diagnostic questions and one or more possible answers to each diagnostic question; a first overlay comprising one or more windows and one or more diagnostic fields, wherein when the first overlay is positioned over the form, the answers to the diagnostic questions that are indicative of the user having a first medical condition are visible through the windows of the first overlay; and wherein the one or more diagnostic fields contain criteria for diagnosing the user with the first medical condition based on the user's selection of answers on the form that are visible through the windows of the first overlay. In other embodiments, the invention is a computer-based version of the diagnostic system and a diagnostic method.
    Type: Application
    Filed: October 8, 2010
    Publication date: March 3, 2011
    Applicant: ASTRAZENECA AB
    Inventors: Fumihiko Sakai, Minoru Hosoda, Itsurou Kobayashi, Shinji Kutukake, Hareaki Yamamoto, Yoneyuki Kobayashi, Kouhei Yamashita, Hajime Baba, Masahiro Kitamura, Toshiyuki Shimizu, Yasuzumi Shimizu
  • CHEMICAL COMPOUNDS 610
    Publication number: 20110053923
    Abstract: There is provided pyrimidinyl indole compounds of Formula (I), or pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: December 21, 2009
    Publication date: March 3, 2011
    Applicant: AstraZeneca
    Inventors: Kevin Michael Foote, Johannes Wilhelmus Maria Nissink
  • NOVEL DIAZASIPIROAKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES
    Publication number: 20110053969
    Abstract: The invention provides compounds of general formula. (II) wherein R and are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: March 30, 2006
    Publication date: March 3, 2011
    Applicant: ASTRAZENECA AB
    Inventors: Stephen Connolly, Marco Skrinjar
  • Benzamide compounds
    Patent number: 7897778
    Abstract: The invention concerns benzamide compounds of Formula (I), wherein R1a, R1b, R1c, R2, R3, R4, m and n have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions which are sensitive to the inhibition of histone deacetylase (HDAC).
    Type: Grant
    Filed: August 31, 2005
    Date of Patent: March 1, 2011
    Assignee: AstraZeneca
    Inventors: Keith Hopkinson Gibson, Elaine Sophie Elizabeth Stokes, Michael James Waring, David Michael Andrews, Zbigniew Stanley Matusiak, Mark Andrew Graham
  • Use for budesonide and formoterol
    Patent number: 7897646
    Abstract: The invention provides the use of formoterol and budesonide in the treatment of chronic obstructive pulmonary disease.
    Type: Grant
    Filed: November 13, 2001
    Date of Patent: March 1, 2011
    Assignee: AstraZeneca AB
    Inventors: Carl-Axel Bauer, Jan Trofast
  • Dry powder inhaler
    Patent number: 7896005
    Abstract: The invention relates to a processing method and apparatus, more particularly, to processing a body so as to remove any electrostatic charge and improve inhaler performance in drug delivery to the respiratory tract.
    Type: Grant
    Filed: October 4, 2004
    Date of Patent: March 1, 2011
    Assignee: AstraZeneca AB
    Inventors: Magnus Olsson, Eva Trofast
  • METHOD FOR PREPARING ADENINE COMPOUND
    Publication number: 20110046369
    Abstract: A method for producing adenine compound (1): wherein m and n are independently an integer of 2 to 5, R1 is C1-6 alkyl group, R2 and R3 are the same or different, and hydrogen atom, or C1-6 alkyl group, or R2 and R3 are combined with an adjacent nitrogen atom to form pyrrolidine, morpholine, piperidine, piperazine, etc., and R4 is C1-3 alkyl group, which comprises a step of reacting compound (2): and compound (3): in the presence of a boron-containing reducing agent.
    Type: Application
    Filed: January 16, 2009
    Publication date: February 24, 2011
    Applicants: DAINIPPON SUMITOMO PHARMA CO., LTD., ASTRAZENECA AKTIEBOLAG
    Inventors: Kazuki Hashimoto, Wataru Katoda, Kazuhiko Takahashi, Ayumu Kurimoto
  • COMBINATION OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST
    Publication number: 20110046191
    Abstract: The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is a selected muscarinic receptor antagonist selected, and a second active ingredient which is a ?2-adrenoceptor agonist, of use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease and asthma.
    Type: Application
    Filed: February 6, 2008
    Publication date: February 24, 2011
    Applicants: ARGENTA DISCOVERY LTD., ASTRAZENECA AB
    Inventors: Finch Harry, Wiley Katherine, Dixon JOhn
  • NEW COMPOUNDS I
    Publication number: 20110046135
    Abstract: The present application relates to new compounds of formula (I), to pharmaceutical compositions comprising the compounds, to processes for their preparation, and to the use of the compounds as leptin receptor modulator mimetics in the preparation of medicaments against conditions associated with weight gain, type 2 diabetes and dyslipidemias.
    Type: Application
    Filed: November 1, 2010
    Publication date: February 24, 2011
    Applicant: ASTRAZENECA AB (PUBL)
    Inventors: Joseph W. Boyd, Giles A. Brown, Michael Higginbottom
  • THERAPEUTIC TREATMENT
    Publication number: 20110046119
    Abstract: A combination comprising candesartan and rosuvastatin for the prevention or treatment of atherosclerosis and for the prevention of cardiovascular events is described.
    Type: Application
    Filed: June 11, 2010
    Publication date: February 24, 2011
    Applicant: AstraZeneca AB
    Inventor: Jay Lal MEHTA
  • PYRIMIDINE DERIVATIVES
    Publication number: 20110046108
    Abstract: The invention concerns benzamide compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, ring A, n, R3, and R4 are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions which are sensitive to the inhibition of EphB4, and/or EphA2 and/or Src kinases.
    Type: Application
    Filed: January 25, 2007
    Publication date: February 24, 2011
    Applicant: AstraZeneca AB
    Inventors: Jason Grant Kettle, Jon Read, Andrew Leach, Bernard Christophe Barlaam, Richard Ducray, Christine Marie Paul Lambert-Van Der Brempt
  • 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
    Patent number: 7893048
    Abstract: Compounds of formula (I): (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.
    Type: Grant
    Filed: June 21, 2006
    Date of Patent: February 22, 2011
    Assignee: AstraZeneca AB
    Inventors: Susanne Alenfalk, Mikael Dahlstrom, Fana Hunegnaw, Staffan Karlsson, Malin Lemurell, Ingemar Starke
  • 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer
    Patent number: 7893063
    Abstract: The invention concerns pyrimidine derivatives of Formula (I) wherein each of Qa, G1, G2, q, R3, r, R4, X1 and Qb have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the production of an anti-proliferative effect in a warm-blooded animal such as man.
    Type: Grant
    Filed: July 7, 2005
    Date of Patent: February 22, 2011
    Assignee: AstraZeneca AB
    Inventor: Martin Pass
  • Novel Compounds
    Publication number: 20110039858
    Abstract: The invention relates to at least one compound of general formula I wherein R1 is phenyl, pyridinyl, thienyl, furanyl, imidazolyl, pyrrolyl, triazolyl, thiazolyl, or pyridine N-oxide, where each R1 phenyl and R1 heteroaromatic ring may optionally and independently be substituted by 1, 2 or 3 substituents selected from CF3, methyl, iodo, bromo, fluoro, and chloro; R2 is independently selected from ethyl and isopropyl; R3 is hydrogen or fluoro; R4 is —NH2 or —NHSO2R5; and R5 is hydrogen, —CF3, or C1-C6 alkyl, or pharmaceutically acceptable salts thereof; at least one process for making at least one compound in accordance with Formula I; at least one method for treating at least one ? receptor associated condition with at least one compound in accordance with Formula I; and at least one pharmaceutical composition comprising at least one compound in accordance with Formula I.
    Type: Application
    Filed: October 25, 2010
    Publication date: February 17, 2011
    Applicant: ASTRAZENECA AB
    Inventors: William Brown, Christopher Walpole, Niklas Plobeck
  • Diagnostic System and Method
    Publication number: 20110040573
    Abstract: A diagnostic system and method. In one embodiment, the invention is a diagnostic system comprising: a form comprising one or more diagnostic questions and one or more possible answers to each diagnostic question; a first overlay comprising one or more windows and one or more diagnostic fields, wherein when the first overlay is positioned over the form, the answers to the diagnostic questions that are indicative of the user having a first medical condition are visible through the windows of the first overlay; and wherein the one or more diagnostic fields contain criteria for diagnosing the user with the first medical condition based on the user's selection of answers on the form that are visible through the windows of the first overlay. In other embodiments, the invention is a computer-based version of the diagnostic system and a diagnostic method.
    Type: Application
    Filed: October 8, 2010
    Publication date: February 17, 2011
    Applicant: ASTRAZENECA AB
    Inventors: Fumihiko Sakai, Minoru Hosoda, Masahiro Kitamura, Toshiyuki Shimizu, Yasuzumi Shimizu, Itsurou Kobayashi, Shinji Kutukake, Hareaki Yamamoto, Yoneyuki Kobayashi, Kouhei Yamashita, Hajime Baba
  • Metabotropic glutamate receptor isoxazole ligands and their use as potentiators
    Patent number: 7888353
    Abstract: Compounds in accord with Formula I: wherein R1, R2, R3 and R4 are as defined in the specification, pharmaceutically acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    Type: Grant
    Filed: August 26, 2010
    Date of Patent: February 15, 2011
    Assignee: AstraZeneca AB
    Inventors: Joseph Cacciola, James Empfield, James Folmer, Angela M Hunter, Scott Throner
  • Process for the preparation of dihydroxy esters and derivatives thereof
    Patent number: 7888083
    Abstract: A process is provided for the preparation of a compound of formula (1) wherein R and R? represent optionally substituted hydrocarbyl groups and X represents a hydrocarbyl linking group. The process comprises either the stereoselective reduction of the keto group in a dihydroxy keto precursor followed by selective esterification of a primary hydroxy, or selective esterification of a primary hydroxy of a dihydroxy keto precursor followed by stereoselective reduction of the keto group.
    Type: Grant
    Filed: April 27, 2010
    Date of Patent: February 15, 2011
    Assignee: AstraZeneca UK Limited
    Inventors: Andrew John Blacker, Christopher David Reeve, Robert Antony Holt